Specialty Drug Costs Continue to Drive Health Care Spending for Public Sector Employers

The National Institute for Public Employee Health Care Policy and the Public Sector HealthCare Roundtable released the 2025 Annual Specialty Drug Survey Report providing analysis of 2024 plan year data from public sector health plans across the country.

The survey includes responses from 23 public sector plan sponsors representing 17 states. Collectively, respondents cover more than 5.5 million beneficiaries and report nearly $30 billion in commercial health care spending, including almost $8 billion in pharmacy benefit spending.

The findings underscore a clear and accelerating trend: specialty drug spending continues to outpace overall health care spending and now accounts for more than half of pharmacy benefit spending for many public sector plans. While employers are deploying a range of strategies to manage costs, the report highlights the need for broader policy solutions to address the structural drivers of specialty drug price growth across the health care system.

The report also outlines 12 policy recommendations aimed at improving transparency, accelerating biosimilar competition, and supporting innovative payment models to ensure sustainable access to life-saving therapies.